Serine 16 phosphorylation induces an order-to-disorder transition in monomeric phospholamban.

Phospholamban (PLB) is a 52 amino acid membrane-endogenous regulator of the sarco(endo)plasmic calcium adenosinetriphosphatase (SERCA) in cardiac muscle. PLB's phosphorylation and dephosphorylation at S16 modulate its regulatory effect on SERCA by an undetermined mechanism. In this paper, we use multidimensional (1)H/(15)N solution NMR methods to establish the structural and dynamics basis for PLB's control of SERCA upon S16 phosphorylation. For our studies, we use a monomeric, fully active mutant of PLB, where C36, C41, and C46 have been mutated to A36, F41, and A46, respectively. Our data show that phosphorylation disrupts the "L-shaped" structure of monomeric PLB, causing significant unwinding of both the cytoplasmic helix (domain Ia) and the short loop (residues 17-21) connecting this domain to the transmembrane helix (domains Ib and II). Concomitant with this conformational transition, we also find pronounced changes in both the pico- to nanosecond and the micro- to millisecond time scale dynamics. The (1)H/(15)N heteronuclear NOE values for residues 1-25 are significantly lower than those of unphosphorylated PLB, with slightly lower NOE values in the transmembrane domain, reflecting less restricted motion throughout the whole protein. These data are supported by the faster spin-lattice relaxation rates (R(1)) present in both the cytoplasmic and loop regions and by the enhanced spin-spin transverse relaxation rates (R(2)) observed in the transmembrane domain. These results demonstrate that while S16 phosphorylation induces a localized structural transition, changes in PLB's backbone dynamics are propagated throughout the protein backbone. We propose that the regulatory mechanism of PLB phosphorylation involves an order-to-disorder transition, resulting in a decrease in the PLB inhibition of SERCA.

[1]  É. Trifilieff,et al.  Evidence for a phosphorylation‐induced conformational change in phospholamban cytoplasmic domain by CD analysis , 1992, FEBS letters.

[2]  A. Szabó,et al.  Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity , 1982 .

[3]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[4]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[5]  David D. Thomas,et al.  Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly coupled to the peptide backbone. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. M. Autry,et al.  Phosphorylation-induced structural change in phospholamban and its mutants, detected by intrinsic fluorescence. , 1998, Biochemistry.

[7]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.

[8]  D. D. Thomas,et al.  Cysteine reactivity and oligomeric structures of phospholamban and its mutants. , 1998, Biochemistry.

[9]  J. Fujii,et al.  Expression and site-specific mutagenesis of phospholamban. Studies of residues involved in phosphorylation and pentamer formation. , 1989, The Journal of biological chemistry.

[10]  D. D. Thomas,et al.  Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. , 2000, Biochemistry.

[11]  D. Maclennan,et al.  Phospholamban Inhibitory Function Is Activated by Depolymerization* , 1997, The Journal of Biological Chemistry.

[12]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[13]  T. Squier,et al.  Conformational changes within the cytosolic portion of phospholamban upon release of Ca-ATPase inhibition. , 2004, Biochemistry.

[14]  E. Kranias,et al.  Functional interplay between dual site phospholambam phosphorylation: insights from genetically altered mouse models , 2002, Basic Research in Cardiology.

[15]  David D. Thomas,et al.  (1)H/(15)N heteronuclear NMR spectroscopy shows four dynamic domains for phospholamban reconstituted in dodecylphosphocholine micelles. , 2004, Biophysical journal.

[16]  S. A. Johnston,et al.  Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase. , 1994, Analytical biochemistry.

[17]  David D. Thomas,et al.  NMR solution structure and topological orientation of monomeric phospholamban in dodecylphosphocholine micelles. , 2003, Biophysical journal.

[18]  David D. Thomas,et al.  Solid-state NMR and rigid body molecular dynamics to determine domain orientations of monomeric phospholamban. , 2002, Journal of the American Chemical Society.

[19]  A. J. Shaka,et al.  Computer-optimized decoupling scheme for wideband applications and low-level operation , 1985 .

[20]  P. Wright,et al.  Suppression of the effects of cross-correlation between dipolar and anisotropic chemical shift relaxation mechanisms in the measurement of spin-spin relaxation rates , 1992 .

[21]  T. Dieterle,et al.  A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  P. Wright,et al.  Intramolecular motions of a zinc finger DNA-binding domain from Xfin characterized by proton-detected natural abundance carbon-13 heteronuclear NMR spectroscopy , 1991 .

[23]  R J Mortishire-Smith,et al.  Solution structure of the cytoplasmic domain of phopholamban: phosphorylation leads to a local perturbation in secondary structure. , 1995, Biochemistry.

[24]  Che Ma,et al.  Deuterium/hydrogen exchange factors measured by solution nuclear magnetic resonance spectroscopy as indicators of the structure and topology of membrane proteins. , 2002, Biophysical journal.

[25]  J. Chrast,et al.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.

[26]  T. Pawson,et al.  Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. , 1994, Biochemistry.

[27]  E. Carafoli,et al.  Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum , 1989, Nature.

[28]  J M Thornton,et al.  Validation of protein models derived from experiment. , 1998, Current opinion in structural biology.

[29]  Ad Bax,et al.  Rapid recording of 2D NMR spectra without phase cycling. Application to the study of hydrogen exchange in proteins , 1989 .

[30]  Baowei Chen,et al.  Phosphorylation induces a conformational transition near the lipid-water interface of phospholamban reconstituted with the Ca-ATPase. , 2002, Biochemistry.

[31]  A. Palmer,et al.  Practical Aspects of Two-Dimensional Proton-Detected 15N Spin Relaxation Measurements , 1993 .

[32]  T. Squier,et al.  Phosphorylation by cAMP-dependent protein kinase modulates the structural coupling between the transmembrane and cytosolic domains of phospholamban. , 2003, Biochemistry.

[33]  W. Huckle,et al.  Characterization and quantitation of phospholamban and its phosphorylation state using antibodies. , 2000, Biochemical and biophysical research communications.

[34]  J. Brender,et al.  Functional dynamics in the active site of the ribonuclease binase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Gräslund,et al.  Micellar systems as solvents in peptide and protein structure determination. , 2001, Methods in enzymology.

[36]  Ad Bax,et al.  Three-dimensional heteronuclear NMR of nitrogen-15 labeled proteins , 1989 .

[37]  S. O. Smith,et al.  Structural perspectives of phospholamban, a helical transmembrane pentamer. , 1997, Annual review of biophysics and biomolecular structure.

[38]  D. D. Thomas,et al.  Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. , 1997, Biochemistry.

[39]  Masahiko Hoshijima,et al.  Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery , 2002, Nature Medicine.

[40]  A. Annila,et al.  Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. , 1999, Biophysical journal.